Hidden Monogenic Diagnoses in Young-Onset Dialysis After Exclusion of Clinically Apparent Polycystic Kidney Disease
- 1Division of Nephrology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Yokohama, Japan; Clinical Genetics and Genomics Center, Sh
Abstract
BackgroundGenomic reassessment may reveal clinically relevant diagnoses in patients with young-onset kidney failure despite established clinical diagnostic labels. We evaluated this approach after excluding clinically apparent polycystic kidney disease (PKD).
MethodsAmong 1,139 patients receiving maintenance dialysis at participating Japanese facilities, 355 had initiated dialysis at age [≤]50 years. After excluding 17 patients with clinically apparent PKD, 108 of 338 eligible patients underwent whole-genome sequencing through voluntary, nonrandom enrollment. Analysis included 465 nuclear candidate genes, mitochondrial DNA, and copy-number/structural variants. Clinically concordant diagnoses were adjudicated using integrated clinical and genetic evidence, with a separate pathogenic/likely pathogenic (P/LP)-supported subset.
ResultsDiagnoses were identified in 10/108 participants (9.3%; 95% confidence interval, 5.1-16.2), comprising seven renal and three systemic/metabolic diagnoses. Nine diagnoses were P/LP-supported (8.3%; 95% confidence interval, 4.4-15.1). The remaining diagnosis was phenotype-based clinical Dent disease associated with a CLCN5 variant of uncertain significance. Diagnoses occurred across diabetic kidney disease, nephrosclerosis, chronic glomerulonephritis, unknown-cause, and other clinical categories. In a post hoc analysis excluding three participants with low target coverage, the integrated and P/LP-supported proportions were 9/105 (8.6%) and 8/105 (7.6%). Six exploratory findings were excluded from both diagnostic numerators. Gitelman syndrome was included as a clinically manifest renal disorder, although its contribution to kidney failure remained uncertain.
ConclusionsIntegrated genomic assessment can uncover renal and systemic/metabolic diagnoses across conventional labels in young-onset kidney failure after exclusion of clinically apparent PKD. Nonrandom enrollment and variable sequencing coverage limit generalizability and interpretation of negative results.
Related
- From Monogenic Variants to Polygenic Risk Scores in Inherited Cardiomyopathies: Clinical Utility, Ancestry Gaps, and Future Implementation in Arab Populations
- National Trends of Chlamydia and Gonorrhea Diagnoses in STD Clinics
- An INSR-BECN1-KIAA0825 complex prevents hepatocytic insulin receptor secretion via extracellular vesicles against monogenic diabetes
- Exploring genetic variants in premature ovarian insufficiency: a cohort-based investigation of monogenic etiologies.
- The monogenic forms of obesity in Saudi families.
BibTeX
@misc{takami2026hidden,
title = {{Hidden Monogenic Diagnoses in Young-Onset Dialysis After Exclusion of Clinically Apparent Polycystic Kidney Disease}},
author = {R. Takami and Y. Sato and K. Higasa and T. Imaizumi and D. Tanaka and D. Yabe and N. Inagaki and T. Oshiro and M. Shimokawa and K. Kawanishi and H. Ito and F. Koiwa},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.17.26365780},
url = {https://www.medrxiv.org/content/10.64898/2026.10.17.26365780v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Hidden Monogenic Diagnoses in Young-Onset Dialysis After Exclusion of Clinically Apparent Polycystic Kidney Disease
AU - R. Takami
AU - Y. Sato
AU - K. Higasa
AU - T. Imaizumi
AU - D. Tanaka
AU - D. Yabe
AU - N. Inagaki
AU - T. Oshiro
AU - M. Shimokawa
AU - K. Kawanishi
AU - H. Ito
AU - F. Koiwa
PY - 2026
DA - 2026/10/17
PB - medRxiv
DO - 10.64898/2026.10.17.26365780
UR - https://www.medrxiv.org/content/10.64898/2026.10.17.26365780v1
AB - BackgroundGenomic reassessment may reveal clinically relevant diagnoses in patients with young-onset kidney failure despite established clinical diagnostic labels. We evaluated this approach after excluding clinically apparent polycystic kidney disease (PKD). MethodsAmong 1,139 patients receiving maintenance dialysis at participating Japanese facilities, 355 had initiated dialysis at age [≤]50 years. After excluding 17 patients with clinically apparent PKD, 108 of 338 eligible patients underwent whole-genome sequencing through voluntary, nonrandom enrollment. Analysis included 465 nuclear candidate genes, mitochondrial DNA, and copy-number/structural variants. Clinically concordant diagnoses were adjudicated using integrated clinical and genetic evidence, with a separate pathogenic/likely pathogenic (P/LP)-supported subset. ResultsDiagnoses were identified in 10/108 participants (9.3%; 95% confidence interval, 5.1-16.2), comprising seven renal and three systemic/metabolic diagnoses. Nine diagnoses were P/LP-supported (8.3%; 95% confidence interval, 4.4-15.1). The remaining diagnosis was phenotype-based clinical Dent disease associated with a CLCN5 variant of uncertain significance. Diagnoses occurred across diabetic kidney disease, nephrosclerosis, chronic glomerulonephritis, unknown-cause, and other clinical categories. In a post hoc analysis excluding three participants with low target coverage, the integrated and P/LP-supported proportions were 9/105 (8.6%) and 8/105 (7.6%). Six exploratory findings were excluded from both diagnostic numerators. Gitelman syndrome was included as a clinically manifest renal disorder, although its contribution to kidney failure remained uncertain. ConclusionsIntegrated genomic assessment can uncover renal and systemic/metabolic diagnoses across conventional labels in young-onset kidney failure after exclusion of clinically apparent PKD. Nonrandom enrollment and variable sequencing coverage limit generalizability and interpretation of negative results.
ER -